SCHEMBL6339246

SCHEMBL6339246

COC(=O)c1ccc(Sc2ccc(OCc3ccccc3)cc2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
RAB9A P51151 6/20 0.49
NPC1 O15118 5/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 1/20 0.48
PARP10 Q53GL7 1/20 0.48
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
SRD5A2 P31213 1/20 0.47
PKM P14618 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
NCOR2 Q9Y618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6347648 0.88 MAOB (0.64) MAOBSMN1; SMN2NR4A1NR4A2NR4A3
SCHEMBL6341711 0.88 NR4A2 (0.62) MAOBSMN1; SMN2MEN1KMT2ANR4A1
SCHEMBL8806506 0.85 MAPK1 (0.54) KMT2ARAB9ANPC1MAPTGAA
SCHEMBL6350325 0.84 MAOB (0.47) MAOBNR4A1NR4A2NR4A3PARP10
SCHEMBL978502 0.81 RAB9A (0.71) MAOBSMN1; SMN2MEN1KMT2ANR4A1
SCHEMBL6348830 0.80 ALDH1A1 (0.50) SMN1; SMN2MEN1KMT2AMAPTGAA
SCHEMBL6347392 0.80 FFAR1 (0.50) MAOBNR4A1NR4A2NR4A3PARP10
SCHEMBL6339006 0.80 OPRM1 (0.57) MAOBSMN1; SMN2MEN1KMT2ANR4A1
SCHEMBL2743634 0.78 BRAF (0.65) GAALMNA
SCHEMBL26169590 0.77 CA1 (0.56) SMN1; SMN2MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1907960-A Anthranilic acid derivatives TEIJIN LTD (JP) 2007-02-07 CN disclosed
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 MAOB 2681/4885SMN1; SMN2 4837/4885MEN1 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.